Nanobiotix share price surpasses €30.50 and posts +46.5% gain in one week

A rebound that positions the stock above all its moving averages

Nanobiotix gains 2.64% to €31.10 during the session, placing it among the strongest gainers in the SBF 120, while the index stagnates.

The gain reaches 46.7% over one week, a movement that contrasts with a quarter still down 11.75%. The price has broken above its high of the last 30 sessions, at €30.50, which has become a support level.

The stock thus stands 34.28% above its 20-day moving average, at €23.16, and also above its 50-day (€28.69) and 200-day (€29.09) moving averages. The RSI at 66 accompanies this recovery, without reaching the overbought zone.

The dual listing, with ADS NBTX on the Nasdaq, reminds us that this is one and the same security listed on two exchanges. The Nasdaq closed at 22:00 yesterday, and its movement can partially affect the Paris opening gap.

First-half results and the ESMO congress fuel the dossier

Upon publication of its first-half 2026 results on September 24, the company indicated it has a cash position of €110.9 million, which should allow it to finance its operations until 2029.

On October 24, at the European Society for Medical Oncology congress in Madrid, Nanobiotix presented a median overall survival of 17.8 months in patients with anti-PD-1 resistant melanoma treated with JNJ-1900 (NBTXR3), radiotherapy and immunotherapy.

On the healthcare front, Sanofi gains 1.06% and Eurofins Scientific 0.94% on October 28. The next level to watch is resistance at €46.18, well above the current price, while support at €30.50 is very close.